المؤلفون: Zwaginga, J.J. (Jaap), Holt, B. (Bronno) van der, Boekhorst, P.A.W. (Peter) te, Biemond, B.J. (Bart), Levin, M.-D. (Mark-David), Griend, R. (René) van der, Brand, A. (Anneke), Zweegman, S. (Sonja), Pruijt, H.F.M. (Hans), Novotny, V.M.J. (Vera), Vreugdenhil, A. (Art), Groot, M.R. (Marco) de, Weerdt, O. (Okke) de, Pampus, E.C.M. (Elisabeth) van, Maanen-Lamme, T.M. (Tanja) van, Wittebol, S. (Shulamit), Schipperus, M.R. (Martin), Silbermann, M.H. (Matthijs), Huijgens, P.C. (Peter), Luten, M. (Marleen), Hollestein, R. (Rene), Brakenhoff, J.A.C. (Jan), Schrama, J.G. (Jolanda), Valster, F.A.A. (Fransje), Velders, G.A. (Gerjo), Koene, H.R. (Harry)

المصدر: Haematologica vol. 100 no. 3, pp. e90-e92

مصطلحات موضوعية: Early response, Immune thrombocytopenia, Open label phase II, Rituximab, Splenectomy delaying

العلاقة: http://repub.eur.nl/pub/89667Test; urn:hdl:1765/89667

الإتاحة: https://doi.org/10.3324/haematol.2014.110213Test
http://repub.eur.nl/pub/89667Test

المؤلفون: Zwaginga, J.J., Holt, B. van der, Boekhorst, P.A. te, Biemond, B.J., Levin, M.D., Griend, R. van der, Brand, A., Zweegman, S., Pruijt, H.F.M., Novotny, V.M.J., Vreugdenhil, A., Groot, M.R. de, Weerdt, O. de, Pampus, E.C.M. van, Maanen-Lamme, T.M. van, Wittebol, S., Schipperus, M.R., Silbermann, M.H., Huijgens, P.C., Luten, M., Hollestein, R., Brakenhoff, J.A.C., Schrama, J.G., Valster, F.A.A., Velders, G.A., Koene, H.R., Dutch HOVON 64 Study Grp

المساهمون: RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Hematology, CCA - Innovative therapy, Erasmus MC other, Clinical Chemistry, Landsteiner Laboratory, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Clinical Haematology, Other departments

المصدر: Zwaginga, JJ, van der Holt, B, te Boekhorst, P A, Biemond, B J, Levin, M D, van der Griend, R, Brand, A, Zweegman, S, Pruijt, H F M, Novotny, V M J, Vreugdenhil, A, de Groot, M R, de Weerdt, O, van Pampus, E C M, van Maanen-Lamme, T M, Wittebol, S, Schipperus, M R, Silbermann, M H, Huijgens, P C, Luten, M, Hollestein, R, Brakenhoff, J A C, Schrama, J G, Valster, F A A, Velders, G A & Koene, H R 2015, ' Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients ', Haematologica, vol. 100, no. 3, pp. E90-E92 . https://doi.org/10.3324/haematol.2014.110213Test
Haematologica, 100, e90-2
Haematologica, 100, 3, pp. e90-2
Haematologica-the Hematology Journal, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), E90-E92
Haematologica, 100(3), E90-E92. Ferrata Storti Foundation
Haematologica, 100(3), e90-e92. Ferrata Storti Foundation

مصطلحات موضوعية: medicine.medical_specialty, Immunologic Factors, Treatment outcome, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Gastroenterology, rituximab, hemic and lymphatic diseases, Internal medicine, Medicine, Dosing, Online Only Articles, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Survival analysis, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Hematology, early response, Immune thrombocytopenia, Treatment efficacy, Surgery, immune thrombocytopenia, splenectomy delaying, Rituximab, Open label, business, open label phase II, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf58d4b2021439809e6420cdc02f1765Test
https://doi.org/10.3324/haematol.2014.110213Test

مصطلحات الفهرس: Early response, Immune thrombocytopenia, Open label phase II, Rituximab, Splenectomy delaying, info:eu-repo/semantics/article

URL: http://repub.eur.nl/pub/89667Test